Testing optimized COVID antiviral treatment in immunocompromised adults
Part of Immune system & allergy, Infections, Lungs & breathing clinical trials.
This study tests the best combination and timing of antiviral medicines for people with COVID-19 who have weakened immune systems. It aims to improve outcomes in people with mild to moderate illness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed COVID-19 on a test (PCR or antigen), done recently enough for the study
- Your symptoms are absent or mild to moderate (not severe breathing failure)
- You are at least 16 years old (or at least 18 in Italy and Norway)
- You have a weakened immune system from an approved list (like certain cancers, HIV with low CD4, long-term immune-suppressing medicines, low blood counts, dialysis, or organ transplant situation)
- You can follow the study rules and sign the consent form
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an optimized antiviral treatment can help people with weakened immune systems who have COVID-19. It aims to find the best way to treat them to prevent severe illness.
This trial tests a longer course of remdesivir plus Paxlovid (nirmatrelvir/ritonavir) for immunocompromised people with persistent COVID-19. It aims to see if combining these two antiviral medicines can help clear the virus more effectively.
This study observes people at higher risk for severe COVID-19 who take Paxlovid, to better understand how well it works and how safe it is in real-world use. It may help doctors confirm the best way to use Paxlovid and spot any side effects.
This trial looks at how well an antiviral works in the body when started early in people with COVID-19 symptoms. You may be able to join if you’re an otherwise healthy adult with confirmed infection and symptoms for less than 4 days.
This study checks how Paxlovid works in everyday care for people who are hospitalized with confirmed COVID-19. If you have a positive COVID-19 test and mild to moderate symptoms, this trial may help doctors understand how well the treatment performs outside of tightly controlled settings.
This trial studies whether PF-07321332 (with ritonavir) helps children under 18 who have COVID-19 at home but are at high risk of severe illness. It looks at whether starting treatment early can reduce progression to worse disease.
Hear when a new COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.